<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00068068</url>
  </required_header>
  <id_info>
    <org_study_id>LSC-OL002</org_study_id>
    <nct_id>NCT00068068</nct_id>
    <nct_alias>NCT00078871</nct_alias>
  </id_info>
  <brief_title>Photodynamic Therapy With Talaporfin Sodium (LS11) in Treating Patients With Refractory Colorectal Liver Metastases</brief_title>
  <official_title>Safety and Efficacy of Treating Refractory Cancers With the Litx™ System: Phase II Safety and Efficacy Study in Patients With Liver Metastases From Colorectal Cancer That Have Failed Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Light Sciences LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Light Sciences LLC</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the Litx platform is safe and effective in&#xD;
      the treatment of liver metastasis arising from colorectal cancer. Litx is a next-generation&#xD;
      photodynamic therapy platform in which the drug, talaporfin sodium (LS11), is activated by&#xD;
      light from the light-emitting diode (LED)-based light infusion device, inserted directly into&#xD;
      the tumor through the skin prior to treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients that provide Informed Consent and satisfy the Eligibility Criteria will undergo CT&#xD;
      or ultrasound guided percutaneous placement of a single, two, three, or four light infusion&#xD;
      devices depending on their tumor characteristics. No more than 4 light sources will be used&#xD;
      at a single treatment. The light infusion devices may be used in a single lesion or in&#xD;
      multiple lesions.&#xD;
&#xD;
      Following radiographic confirmation of light infusion device placement, patients will receive&#xD;
      an intravenous dose of LS11 at 40 mg/m². One hour following completion of LS11&#xD;
      administration, delivery of 200 J/cm light energy will begin. The light infusion device will&#xD;
      then be manually removed and the patients will be observed for acute complication of light&#xD;
      infusion device removal. Precautions for protection from external light exposure should be&#xD;
      instituted beginning with the LS11 administration and be maintained as defined throughout the&#xD;
      study period. On day 30+5 the patient will undergo clinical assessment and the tumor mass&#xD;
      will be imaged using contrast enhanced spiral CT for determination of volume and radius of&#xD;
      the tumor size, as well as tumor necrosis. The patient may then receive 5-FU and/or&#xD;
      leucovorin + either irinotecan or oxaliplatin standard chemotherapy at day 30 visit. All&#xD;
      patients, with or without chemotherapy at day 30, will undergo final clinical assessment and&#xD;
      final tumor imaging evaluation using contrast CT at day 60+5 of Litx treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>25</enrollment>
  <condition>Liver Metastasis</condition>
  <condition>Colorectal Neoplasms</condition>
  <condition>Liver Neoplasms</condition>
  <condition>Neoplasm Metastasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Talaporfin sodium (LS11)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LED-based light infusion device</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Light emitting diodes (LED)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Photodynamic therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Phototherapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Patients with metastatic liver lesions from colorectal disease who have failed or&#xD;
             progressed on a chemotherapy regimen for metastatic disease.&#xD;
&#xD;
          -  Biopsy proven evidence of colorectal cancer.&#xD;
&#xD;
          -  Patients with 4 or fewer lesions greater than 1 cm and with no single lesion greater&#xD;
             than 7 cm in maximum diameter.&#xD;
&#xD;
          -  Age greater than or equal to 18 years.&#xD;
&#xD;
          -  Patients must be able to sign informed consent.&#xD;
&#xD;
          -  Life expectancy greater than or equal to 3 months.&#xD;
&#xD;
          -  ECOG performance status 0-2.&#xD;
&#xD;
          -  Patients with extrahepatic disease in addition to their hepatic metastases are&#xD;
             eligible and will receive systemic therapy for their extrahepatic disease following&#xD;
             Litx therapy.&#xD;
&#xD;
          -  Off chemotherapy for 4 weeks. Must have recovered from the chemotherapy effects.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Patients must be excluded if any of the following apply:&#xD;
&#xD;
          -  Patients who are candidates for complete surgical resection.&#xD;
&#xD;
          -  Pregnancy or breast-feeding. A negative pregnancy test (urine or serum) is required&#xD;
             prior to enrollment.&#xD;
&#xD;
          -  Known uncontrollable serious reactions such as anaphylaxis, to the contrast agents&#xD;
             used in this study.&#xD;
&#xD;
          -  PT or PTT greater than 1.5X control.&#xD;
&#xD;
          -  Platelet count less than 100,000.&#xD;
&#xD;
          -  WBC less than 2500/mm.&#xD;
&#xD;
          -  Neutrophils less than 2000/mm.&#xD;
&#xD;
          -  Hemoglobin less than 9 g/dL.&#xD;
&#xD;
          -  Liver enzymes greater than 3 X ULN.&#xD;
&#xD;
          -  Total bilirubin greater than 1.5 X ULN.&#xD;
&#xD;
          -  Serum creatinine greater than 2.5 X ULN.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>HealthOne Alliance/Presbyterian St. Lukes Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Carolina University, School of Medicine</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27858</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania / Department of Radiation Oncology</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Frankfurt, Johann Wolfgang Goethe-University</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>D-60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lightsciences.com</url>
    <description>Sponsor website</description>
  </link>
  <reference>
    <citation>Chen J, Keltner L, Christophersen J, Zheng F, Krouse M, Singhal A, Wang SS. New technology for deep light distribution in tissue for phototherapy. Cancer J. 2002 Mar-Apr;8(2):154-63.</citation>
    <PMID>11999949</PMID>
  </reference>
  <reference>
    <citation>Lustig RA, Vogl TJ, Fromm D, Cuenca R, Alex Hsi R, D'Cruz AK, Krajina Z, Turić M, Singhal A, Chen JC. A multicenter Phase I safety study of intratumoral photoactivation of talaporfin sodium in patients with refractory solid tumors. Cancer. 2003 Oct 15;98(8):1767-71.</citation>
    <PMID>14534895</PMID>
  </reference>
  <verification_date>September 2006</verification_date>
  <study_first_submitted>September 4, 2003</study_first_submitted>
  <study_first_submitted_qc>September 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2003</study_first_posted>
  <last_update_submitted>September 18, 2006</last_update_submitted>
  <last_update_submitted_qc>September 18, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2006</last_update_posted>
  <keyword>Photodynamic therapy</keyword>
  <keyword>Liver metastases</keyword>
  <keyword>Colorectal cancer</keyword>
  <keyword>Litx™</keyword>
  <keyword>Light Infusion Technology™</keyword>
  <keyword>Talaporfin sodium</keyword>
  <keyword>LS11</keyword>
  <keyword>Liver mets</keyword>
  <keyword>Metastatic colorectal cancer</keyword>
  <keyword>Light emittting diodes (LED)</keyword>
  <keyword>Tumor ablation</keyword>
  <keyword>Combination therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Talaporfin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

